Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of foritinib succinate versus crizotinib in treatment-naive ALK-positive advanced or metastatic NSCLC
CTR20213144Phase 3Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer comparing Foritinib succinate with Crizotinib (2 arms). Primary endpoint: Progression-free survival. Started Dec 2021; status: active.
02
Drugs
foritinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20213144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213144.